The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study on lenvatinib (LEN) in recurrent and/or metastatic (R/M) adenoid cystic carcinomas (ACC) of the salivary glands (SG) of the upper aereodigestive tract (NCT02860936).
 
Laura Locati
Consulting or Advisory Role - Eisai; Ipsen
Speakers' Bureau - Eisai
 
Donata Galbiati
No Relationships to Disclose
 
Giuseppina Calareso
No Relationships to Disclose
 
Salvatore Alfieri
No Relationships to Disclose
 
Roberta Granata
No Relationships to Disclose
 
Paolo Bossi
Honoraria - Kyowa Hakko Kirin; MSD Oncology; Prostrakan
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Helsinn Therapeutics; Merck Serono; Mundipharma; Tesaro
Research Funding - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); Exelixis (Inst); Helsinn Therapeutics (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
 
Cristiana Bergamini
No Relationships to Disclose
 
Carlo Resteghini
No Relationships to Disclose
 
Stefano Cavalieri
No Relationships to Disclose
 
Francesca Platini
No Relationships to Disclose
 
Pasquale Quattrone
No Relationships to Disclose
 
Moela Mancinelli
No Relationships to Disclose
 
Andrea Zucchella
No Relationships to Disclose
 
Luigi Mariani
No Relationships to Disclose
 
Guido Fedele
No Relationships to Disclose
 
Lisa F. Licitra
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Debiopharm Group; Eisai; Merck Serono; MSD; Novartis; Roche; SOBI
Research Funding - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Debiopharm Group; Merck Serono; SOBI